or Try an Advanced Search...

    Technical Analysis for GERN - Geron Corporation

    Grade Last Price % Change Price Change
    C 3.99 5.28% 0.20
    GERN closed up 5.28 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical GERN trend table...
    Date Alert Name Type % Chg
    Crossed Above 200 DMA Bullish 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Up 3 Days in a Row Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Lower Bollinger Band Walk Weakness 5.28%
    Inside Day Range Contraction 5.28%
    Lower Bollinger Band Touch Weakness 5.28%
    Oversold Stochastic Weakness 5.28%
    200 DMA Resistance Bearish 5.56%
    Stochastic Buy Signal Bullish 5.56%
    Older End-of-Day Signals for GERN ...

       Recent Intraday Alerts

    Alert Time
    Up 1 ATR about 19 hours ago
    Up 5% about 19 hours ago
    Rose Above 10 DMA about 20 hours ago
    Up 3% about 20 hours ago
    Rose Above 200 DMA about 21 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    GERN Chart by TradingView
    Basic chart:

    Profile

    Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Biology Stem Cell Senescence Geron Corporation Haematopoiesis

    Is GERN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 11 Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development
    Nov 11 Geron to Participate in the Stifel 2024 Healthcare Conference
    Nov 10 Analysts Are Upgrading Geron Corporation (NASDAQ:GERN) After Its Latest Results
    Nov 9 Geron Third Quarter 2024 Earnings: Beats Expectations
    Nov 8 Geron Corp (GERN) Q3 2024 Earnings Call Highlights: Strong Rytelo Launch and Strategic ...
    Nov 8 Geron Secures $250M Funding and Strong Q3 Sales
    Nov 8 Tezspire succeeds in chronic rhinosinusitis; Gilead writes down Trodelvy value
    Nov 7 Geron (GERN) Q3 2024 Earnings Call Transcript
    Nov 7 Geron: A Post Earnings And Funding Announcement Assessment
    Nov 7 Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors
    See more GERN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.34
    52 Week Low 1.64
    Average Volume 8,928,909
    200-Day Moving Average 3.87
    50-Day Moving Average 4.23
    20-Day Moving Average 4.05
    10-Day Moving Average 3.94
    Average True Range 0.21
    RSI (14) 47.09
    ADX 23.85
    +DI 17.01
    -DI 20.95
    Chandelier Exit (Long, 3 ATRs) 3.87
    Chandelier Exit (Short, 3 ATRs) 4.23
    Upper Bollinger Bands 4.44
    Lower Bollinger Band 3.66
    Percent B (%b) 0.42
    BandWidth 19.27
    MACD Line -0.11
    MACD Signal Line -0.09
    MACD Histogram -0.0204
    Fundamentals Value
    Market Cap 2.17 Billion
    Num Shares 543 Million
    EPS -0.34
    Price-to-Earnings (P/E) Ratio -11.74
    Price-to-Sales 3614.72
    Price-to-Book 3.94
    PEG Ratio -2.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.40
    Resistance 3 (R3) 4.36 4.18 4.33
    Resistance 2 (R2) 4.18 4.07 4.20 4.31
    Resistance 1 (R1) 4.09 4.01 4.13 4.13 4.29
    Pivot Point 3.91 3.91 3.93 3.93 3.91
    Support 1 (S1) 3.81 3.80 3.86 3.85 3.69
    Support 2 (S2) 3.63 3.74 3.65 3.67
    Support 3 (S3) 3.54 3.63 3.65
    Support 4 (S4) 3.58